Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Senores Pharma.
Quarter-by-quarter operating performance
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 79 | 102 | 80 | 101 | 103 | 114 | 138 | 162 | 171 | 175 |
| Expenses + | 64 | 80 | 59 | 77 | 77 | 95 | 104 | 112 | 121 | 128 |
| Operating Profit | 15 | 22 | 21 | 23 | 26 | 19 | 34 | 50 | 50 | 47 |
| OPM % | 19% | 22% | 27% | 23% | 25% | 17% | 25% | 31% | 29% | 27% |
| Other Income + | 1 | 2 | 0 | 2 | 5 | 12 | 3 | 5 | 7 | 18 |
| Interest | 2 | 3 | 5 | 5 | 6 | 5 | 5 | 6 | 5 | 8 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 6 | 8 | 8 | 9 |
| Profit before tax | 10 | 18 | 13 | 16 | 20 | 21 | 26 | 41 | 45 | 47 |
| Tax % | 31% | 19% | 19% | 18% | 20% | 13% | 20% | 26% | 25% | 23% |
| Net Profit + | 7 | 14 | 11 | 13 | 16 | 18 | 21 | 30 | 34 | 37 |
| EPS in Rs | 2.37 | 5.23 | 3.23 | 3.86 | 3.73 | 3.87 | 4.28 | 7.03 | 6.87 | 6.86 |
Financials of Senores Pharma.
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales + | 14 | 35 | 215 | 398 | 633 |
| Expenses + | 12 | 23 | 173 | 309 | 464 |
| Operating Profit | 2 | 13 | 42 | 90 | 168 |
| OPM % | 14% | 36% | 19% | 23% | 27% |
| Other Income + | 0 | 4 | 3 | 19 | 47 |
| Interest | 1 | 2 | 9 | 22 | 25 |
| Depreciation | 1 | 2 | 10 | 17 | 31 |
| Profit before tax | 1 | 12 | 25 | 71 | 159 |
| Tax % | 13% | 32% | -31% | 17% | 24% |
| Net Profit + | 1 | 8 | 33 | 58 | 122 |
| EPS in Rs | 1.01 | 8.59 | 10.31 | 12.72 | 25.05 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Financials of Senores Pharma.
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 9 | 10 | 31 | 46 | 46 |
| Reserves | 28 | 36 | 174 | 740 | 888 |
| Borrowings + | 15 | 63 | 258 | 315 | 342 |
| Other Liabilities + | 8 | 23 | 160 | 126 | 328 |
| Total Liabilities | 59 | 131 | 622 | 1,227 | 1,604 |
| Fixed Assets + | 7 | 27 | 235 | 301 | 755 |
| CWIP | 8 | 34 | 97 | 172 | 17 |
| Investments | 15 | 16 | 0 | 0 | 4 |
| Other Assets + | 29 | 53 | 289 | 754 | 827 |
| Total Assets | 59 | 131 | 622 | 1,227 | 1,604 |
Financials of Senores Pharma.
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | -10 | -1 | -26 | -46 | 62 |
| Cash from Investing Activity + | -24 | -48 | -54 | -429 | -121 |
| Cash from Financing Activity + | 36 | 46 | 87 | 573 | -1 |
| Net Cash Flow | 2 | -3 | 8 | 98 | -60 |
| Free Cash Flow | -21 | -48 | -78 | -203 | -203 |
| CFO/OP | -526% | 3% | -56% | -41% | 45% |
Financials of Senores Pharma.
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 506 | 228 | 191 | 114 | 187 |
| Inventory Days | 135 | 89 | 184 | 232 | 130 |
| Days Payable | 324 | 388 | 556 | 275 | 340 |
| Cash Conversion Cycle | 317 | -71 | -182 | 70 | -24 |
| Working Capital Days | 359 | -7 | -16 | 88 | 132 |
| ROCE % | 18% | 12% | 11% | 15% |
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…